Change over period: —
NSE · JUBLPHARMA
JUBLPHARMA
-19.4% from the 52-week high · +15.6% above the low
Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. The company is headquartered in Noida, Uttar Pradesh and currently employs 1,034 full-time employees. The firm's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
The short version. JUBLPHARMA reported revenue of ₹2,370 crore for Sep 2026, up 20.5% from a year earlier. Net profit was ₹31 crore (down 74.2% year on year). Return on equity was 5.6% in Mar 2026. Promoter holding was 47.68% in Sep 2026, down 3.00 points over 8 quarters.
1 · The price
How has the stock traded?
JUBLPHARMA trades 19.4% below its 52-week high and 15.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹2,370 cr.
Sep 2026 net profit of ₹31 cr.
4.8 pts lower than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2370 | 2229 | 2290 | 2122 | 1966 | 1901 | 1929 | 1822 |
| Net profit | 31 | 56 | 119 | 56 | 120 | 103 | 154 | 101 |
| Net margin % | 1.3 | 2.5 | 5.2 | 2.6 | 6.1 | 5.4 | 8.0 | 5.5 |
| EPS (₹) | 1.96 | 3.55 | 7.5 | 3.51 | 7.55 | 6.46 | 9.64 | 6.33 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8280 | 7234 | 6703 | 6282 | 6059 | 6099 | 9154 | 9111 |
| Net profit | 398 | 839 | 77 | -61 | 414 | 836 | 898 | 574 |
| Net margin % | 4.8 | 11.6 | 1.2 | -1.0 | 6.8 | 13.7 | 9.8 | 6.3 |
| EPS (₹) | 25.02 | 52.7 | 4.84 | -3.83 | 25.99 | 52.48 | 56.39 | 36.07 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 5.6% in Mar 2026; debt to equity is 0.45.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 5.6 | 13.4 | 14.2 | -1.1 |
| Return on capital % | 6.4 | 11.5 | 43.4 | 2.2 |
| EBITDA margin % | 15.2 | 21.8 | 11.8 | 12.0 |
| Net margin % | 4.8 | 11.5 | 1.1 | -1.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 9.7% | 6.4% |
| Profit CAGR | — | -13.8% |
4 · The owners
Who holds it, and are they adding?
Down 3.0 pts over 8 quarters.
Down 1.58 pts over 8 quarters.
Up 6.04 pts over 8 quarters.
+7 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.68 | 50.68 | 47.68 | 47.68 | 47.68 | 47.68 | 47.68 | 47.68 | -3.0 |
| FII | 16.96 | 17.22 | 17.4 | 16.57 | 15.96 | 15.9 | 15.87 | 15.38 | -1.58 |
| DII | 6.98 | 7.05 | 9.53 | 10.52 | 11.22 | 11.62 | 12.4 | 13.02 | +6.04 |
| Public | 24.83 | 24.5 | 24.84 | 24.6 | 24.57 | 24.24 | 23.5 | 23.38 | -1.45 |
Mutual fund holdings · Oct 2026
34 schemes hold this stock
27 the month before.
- Bandhan Focused Fund5.92% of NAV
- Kotak Consumption Fund1.61% of NAV
- Bandhan Small Cap Fund1.56% of NAV
- Kotak Special Opportunities Fund1.46% of NAV
- THE WEALTH COMPANY MULTI CAP FUND1.3% of NAV
- Abakkus Small Cap Fund1.29% of NAV
- Abakkus Large & Mid Cap Fund1.28% of NAV
- Kotak Healthcare Fund1.08% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for JUBLPHARMA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about JUBLPHARMA
What is the JUBLPHARMA share price?
JUBLPHARMA (JUBLPHARMA) last closed at ₹933.25, down 0.04% on the day. Its 52-week range is ₹807.65 to ₹1,158.90.
What is the market cap of JUBLPHARMA?
JUBLPHARMA has a market capitalisation of about ₹14,796 crore. Its price-to-earnings ratio is 35.7.
How are JUBLPHARMA's latest results?
JUBLPHARMA reported revenue of ₹2,370 crore for Sep 2026, up 20.5% from a year earlier. Net profit was ₹31 crore (down 74.2% year on year). Return on equity was 5.6% in Mar 2026. Promoter holding was 47.68% in Sep 2026, down 3.00 points over 8 quarters.
Who owns JUBLPHARMA?
As of Sep 2026, shareholding was: Promoter 47.68%, FII 15.38%, DII 13.02%, Public 23.38%.
How many mutual funds hold JUBLPHARMA?
34 mutual fund schemes held JUBLPHARMA in October 2026. That compares with 27 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 25 Jul 2025 · Final Dividend - Rs. 5
- 02 Aug 2024 · Final Dividend - Rs. 5
- 10 Aug 2023 · Final Dividend - Rs. 5
- 11 Aug 2022 · Final Dividend - Rs. 5
- 05 Aug 2021 · Final Dividend - Rs. 5
- 09 Mar 2020 · Interim Dividend - Rs. 5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.